Everfront Biotech Holding Company Limited (EFB)

EFB Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	0.43	1.22	0.55
Short-Term Investments	-	0.01	-
Cash & Cash Equivalents	0.43	1.23	0.55
Cash Growth	-	124.13%	-
Receivables	-	0	-
Other Current Assets	0.44	0.46	0.44
Total Current Assets	0.87	1.69	0.99
Property, Plant & Equipment	-	0.03	0.01
Goodwill and Intangibles	-	0.34	0.35
Other Long-Term Assets	-	0	0
Total Long-Term Assets	-	0.37	0.36
Total Assets	-	2.07	1.35
Current Debt	-	2.52	0.01
Other Current Liabilities	2.65	0.16	0.16
Total Current Liabilities	2.65	2.68	0.17
Long-Term Debt	-	0.01	0
Total Long-Term Liabilities	-	0.01	0
Total Liabilities	-	2.69	0.18
Total Debt	2.53	2.53	0.01
Debt Growth	-	22272.22%	-
Retained Earnings	-	-20	-17.71
Comprehensive Income	-	-0.24	-0.23
Shareholders' Equity	-1.45	-0.62	1.18
Net Cash / Debt	-2.1	-1.3	0.54
Working Capital	-1.78	-0.99	0.82

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).